Medical Marijuana Inc (MJNA)

[mjtruth]

that's not what the DEA and FDA registered facility says that performed the lab test check out this post and link Doc K. EXTREMELY valuable DD ! YUUUUUUP GO MJNA BUTANE and ETHYL ACETATE YUUUUP TOOOO THHHHEEEEEEE MOOOOON !!!!!!!!! $42.00 BY DECEMBER YUUUUUUUP

Quote:
The three RSHO Blue samples tested clean. But Dr. Noel Palmer found significant levels of hexane,a highly toxic industrial solvent, in both RSHO Gold vials.102 Symptoms of hexane poisoning include nausea, vomiting, headaches, dizziness, and mental confusion. Concentrations of hexane in excess of 50 grams can be fatal.103
Chromatographs of the RSHO Gold samples also showed a second major peak, presumably another
chlorinated solvent, which PhytaTech was unable to identify due to equipment limitations (see
Appendix C).
In an effort to verify PhytaTech’s findings and identify the mystery peak, Project CBD contacted
Flora Research Laboratories, a DEA and FDA registered facility in Grants Pass, Oregon, which
agreed to examine the two RSHO Gold samples strictly because of public health and safety
concerns, not for commercial purposes.
James Neal-Kababick, director of Flora Research Laboratories, confirmed the presence of significant
levels of hexane and other solvent residues in the RSHO Gold sample from Krenzler (see Appendix
D). 104 A smorgasbord of contaminants were found in this item, including variants of pentane,
butane, and ethyl acetate (as in nail polish remover).
These are all “class one solvents, the most dangerous and toxic class of solvents,” explained Dr.
Jahan Marcu, a Project CBD science consultant.
In his lab analysis, Neal-Kababick noted that the first sample he tested ended up clogging his
equipment: “Major residue left on needle and found on vented caps of used vials…. Ran multiple
vials of water to clean system of carryover. . . . Carryover dissolved after triplicate runs of water
vials.” Neal-Kababick had never encountered such a problem before: “Carryover issues not
observed in historical samples of other matrices tested.”106
These carryover issues may have been a factor as Neal-Kababick was unable to conduct a
satisfactory analysis of the second RSHO Gold sample from the Crohn’s patient. That sample
showed no peaks at all, underscoring the need for another battery of tests, which are pending.


http://www.projectcbd.org/news/hemp-oil-hustlers-a-project-cbd-special-report-on-medical-marijuana-inc-hempmeds-and-kannaway/